Reproducing Protocol‐Based Studies Using Parameterizable Tools—Comparison of Analytic Approaches Used by Two Medical Product Surveillance Networks
暂无分享,去创建一个
Richard Platt | Robert W. Platt | Robert W Platt | Sengwee Toh | Judith C Maro | Laurent Azoulay | Ting-Ying Huang | Emily C Welch | Mayura U Shinde | Kristian B Filion | R. Platt | K. Filion | S. Toh | J. Maro | Mayura U. Shinde | L. Azoulay | E. Welch | Ting-Ying Huang
[1] Robert W. Platt,et al. Observational Studies of Drug Safety in Multi-Database Studies: Methodological Challenges and Opportunities , 2016, EGEMS.
[2] Sebastian Schneeweiss,et al. Choosing Among Common Data Models for Real‐World Data Analyses Fit for Making Decisions About the Effectiveness of Medical Products , 2020, Clinical pharmacology and therapeutics.
[3] Robert W. Platt,et al. Distributed Networks of Databases Analyzed Using Common Protocols and/or Common Data Models , 2019, Pharmacoepidemiology.
[4] Sebastian Schneeweiss,et al. A basic study design for expedited safety signal evaluation based on electronic healthcare data , 2010, Pharmacoepidemiology and drug safety.
[5] A. Levy,et al. CNODES: the Canadian Network for Observational Drug Effect Studies , 2012, Open medicine : a peer-reviewed, independent, open-access journal.
[6] Richard Platt,et al. The organizational structure and governing principles of the Food and Drug Administration's Mini‐Sentinel pilot program , 2012, Pharmacoepidemiology and drug safety.
[7] D. Rubin,et al. The central role of the propensity score in observational studies for causal effects , 1983 .
[8] Pierre Ernst,et al. Association Between Incretin-Based Drugs and the Risk of Acute Pancreatitis. , 2016, JAMA internal medicine.
[9] Moride Yola,et al. Evidence of the depletion of susceptibles effect in non-experimental pharmacoepidemiologic research. , 1994 .
[10] Olaf Klungel,et al. The reporting of studies conducted using observational routinely collected health data statement for pharmacoepidemiology (RECORD-PE) , 2018, British Medical Journal.
[11] Robert W. Platt,et al. How pharmacoepidemiology networks can manage distributed analyses to improve replicability and transparency and minimize bias , 2020, Pharmacoepidemiology and drug safety.
[12] Marsha A Raebel,et al. Design considerations, architecture, and use of the Mini‐Sentinel distributed data system , 2012, Pharmacoepidemiology and drug safety.
[13] Richard Platt,et al. The FDA Sentinel Initiative - An Evolving National Resource. , 2018, The New England journal of medicine.
[14] Til Stürmer,et al. Indications for propensity scores and review of their use in pharmacoepidemiology. , 2006, Basic & clinical pharmacology & toxicology.
[15] Jerry H. Gurwitz,et al. A systematic review of validated methods for identifying heart failure using administrative data , 2012, Pharmacoepidemiology and drug safety.
[16] Sengwee Toh,et al. Confounding adjustment via a semi‐automated high‐dimensional propensity score algorithm: an application to electronic medical records , 2011, Pharmacoepidemiology and drug safety.
[17] Jerry H. Gurwitz,et al. Mini-Sentinel Systematic Evaluation of Health Outcome of Interest Definitions for Studies Using Administrative and Claims Data: Heart Failure , 2012 .
[18] Y. Moride,et al. Evidence of the depletion of susceptibles effect in non-experimental pharmacoepidemiologic research. , 1994, Journal of clinical epidemiology.
[19] Olaf Klungel,et al. Reporting to Improve Reproducibility and Facilitate Validity Assessment for Healthcare Database Studies V1.0. , 2017, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[20] Bruce H Fireman,et al. Confounding Adjustment in Comparative Effectiveness Research Conducted Within Distributed Research Networks , 2013, Medical care.
[21] S Toh,et al. Successful Comparison of US Food and Drug Administration Sentinel Analysis Tools to Traditional Approaches in Quantifying a Known Drug‐Adverse Event Association , 2016, Clinical pharmacology and therapeutics.
[22] W. Ray,et al. Evaluating medication effects outside of clinical trials: new-user designs. , 2003, American journal of epidemiology.
[23] Sengwee Toh,et al. Analyzing partially missing confounder information in comparative effectiveness and safety research of therapeutics , 2012, Pharmacoepidemiology and drug safety.
[24] M Maclure,et al. Performance of comorbidity scores to control for confounding in epidemiologic studies using claims data. , 2001, American journal of epidemiology.
[25] Barbara Evans,et al. A policy framework for public health uses of electronic health data , 2012, Pharmacoepidemiology and drug safety.
[26] Pierre Ernst,et al. A Multicenter Observational Study of Incretin-based Drugs and Heart Failure. , 2016, The New England journal of medicine.
[27] James M. Robins,et al. Observational Studies Analyzed Like Randomized Experiments: An Application to Postmenopausal Hormone Therapy and Coronary Heart Disease , 2008, Epidemiology.
[28] Sebastian Schneeweiss,et al. A combined comorbidity score predicted mortality in elderly patients better than existing scores. , 2011, Journal of clinical epidemiology.
[29] P. Rosenbaum,et al. Invited commentary: propensity scores. , 1999, American journal of epidemiology.
[30] Charles E. Leonard,et al. Evaluation of the US Food and Drug Administration sentinel analysis tools in confirming previously observed drug‐outcome associations: The case of clindamycin and Clostridium difficile infection , 2018, Pharmacoepidemiology and drug safety.
[31] Christian Hampp,et al. Sentinel Modular Program for Propensity Score–Matched Cohort Analyses: Application to Glyburide, Glipizide, and Serious Hypoglycemia , 2017, Epidemiology.
[32] R. Platt,et al. Developing the Sentinel System--a national resource for evidence development. , 2011, The New England journal of medicine.
[33] Sengwee Toh,et al. Development and Application of Two Semi-Automated Tools for Targeted Medical Product Surveillance in a Distributed Data Network , 2017, Current Epidemiology Reports.
[34] S. Anderson,et al. The FDA's sentinel initiative—A comprehensive approach to medical product surveillance , 2016, Clinical pharmacology and therapeutics.
[35] Richard Platt,et al. The U.S. Food and Drug Administration's Mini‐Sentinel program: status and direction , 2012, Pharmacoepidemiology and drug safety.
[36] R. Carnahan,et al. A systematic review of validated methods for identifying pancreatitis using administrative data , 2012, Pharmacoepidemiology and drug safety.
[37] Christian Hampp,et al. Evaluation of the US Food and Drug Administration Sentinel Analysis Tools Using a Comparator with a Different Indication: Comparing the Rates of Gastrointestinal Bleeding in Warfarin and Statin Users , 2019, Pharmaceutical Medicine.